Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q3 2025 value amounting to $56.2 million.

  • Verrica Pharmaceuticals' Total Non-Current Liabilities changed N/A to $56.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year change of. This contributed to the annual value of $61.3 million for FY2024, which is 78.92% down from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Total Non-Current Liabilities of $56.2 million as of Q3 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $61.8 million in Q4 2023 and a low of $6.8 million during Q2 2023
  • Over the past 3 years, Verrica Pharmaceuticals' median Total Non-Current Liabilities value was $56.2 million (recorded in 2025), while the average stood at $50.6 million.
  • The largest annual percentage gain for Verrica Pharmaceuticals' Total Non-Current Liabilities in the last 5 years was 78.92% (2024), contrasted with its biggest fall of 78.92% (2024).
  • Quarter analysis of 3 years shows Verrica Pharmaceuticals' Total Non-Current Liabilities stood at $61.8 million in 2023, then dropped by 0.79% to $61.3 million in 2024, then dropped by 8.43% to $56.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $56.2 million for Q3 2025, versus $54.8 million for Q2 2025 and $58.4 million for Q1 2025.